Brolucizumab versus Aflibercept in Patients with Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled Trials
Brolucizumab was non-inferior in functional outcomes and was superior to aflibercept in anatomical parameters. Ocular AEs and AESIs were numerically low and not statistically significant. Our findings underscore the importance of new RCTs powered to assess safety outcomes in order to suggest brolucizumab as an alternative to the treatment of DME.
Authors
- Jonathan T. Caranfa (ORCID: https://orcid.org/0000-0002-3476-3431)
- Fabrissio P. Graffunder (ORCID: https://orcid.org/0000-0002-0224-846X)
- William W. Binotti (ORCID: https://orcid.org/0000-0001-6761-8807)
- Leonardo Busch Justino (ORCID: https://orcid.org/0000-0002-6267-3214)
- Gustavo Busch Justino (ORCID: https://orcid.org/0000-0001-7500-8603)
- Ali Khodor (ORCID: https://orcid.org/0009-0004-8752-919X)
Institutions
- Tufts Medical Center (US)
- University of Miami (US)
- Universidade Federal de Santa Catarina (BR)
- Governador Celso Ramos Hospital (BR)
Publication Details
- Journal
- Clinical ophthalmology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/opth.s487055
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.08